Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

THAR

Tharimmune Inc

Dec 26 • 09:48AM ET

2.13

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY JNJ AMGN MRK VRTX REGN PFE BIIB BMY GILD

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.91	Insider Own	1.79%	Shs Outstand	1.49M	Perf Week	1.43%
Market Cap	3.17M	Forward P/E	-	EPS next Y	-2.11	Insider Trans	178.66%	Shs Float	1.46M	Perf Month	-13.06%
Income	-10.85M	PEG	-	EPS next Q	-1.53	Inst Own	1.63%	Short Float	6.12%	Perf Quarter	-13.41%
Sales	0.00M	P/S	-	EPS this Y	92.16%	Inst Trans	218.22%	Short Ratio	0.07	Perf Half Y	-34.06%
Book/sh	2.35	P/B	0.91	EPS next Y	74.88%	ROA	-257.79%	Short Interest	0.09M	Perf Year	-71.84%
Cash/sh	3.20	P/C	0.67	EPS next 5Y	-	ROE	-454.53%	52W Range	1.84 - 8.42	Perf YTD	-72.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.82%	ROI	-359.59%	52W High	-74.70%	Beta	1.29
Dividend TTM	-	Quick Ratio	2.30	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.08%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	2.30	EPS Y/Y TTM	95.51%	Oper. Margin	-	RSI (14)	45.81	Volatility	5.31% 7.79%
Employees	2	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	93.78%	Payout	-	Rel Volume	0.03	Prev Close	2.13
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	1.24M	Price	2.13
SMA20	-1.32%	SMA50	-7.34%	SMA200	-41.67%	Trades		Volume	3,838	Change	0.00%

Dec-16-24 08:00AM	Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update (ACCESSWIRE)
Dec-06-24 04:15PM	Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs (ACCESSWIRE) +10.84%
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-18-24 08:00AM	Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease (ACCESSWIRE) +9.22%
Nov-13-24 08:00AM	Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics (ACCESSWIRE)
09:00AM	Loading…
Nov-04-24 09:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE) +9.67%
Oct-30-24 08:00AM	Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) +68.97%
Oct-28-24 09:00AM	Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting (ACCESSWIRE)
Oct-25-24 08:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE)
Sep-30-24 07:00AM	Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company (ACCESSWIRE)
Sep-16-24 07:00AM	Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab (ACCESSWIRE)
Jul-22-24 08:30AM	Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board (ACCESSWIRE)
Jul-17-24 08:30AM	Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor (ACCESSWIRE) -15.40%
Jul-16-24 08:30AM	Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 (ACCESSWIRE)
Jun-10-24 08:00AM	Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -33.27%
08:30AM	Loading…
May-29-24 08:30AM	Tharimmune to Present at 2024 BIO International Convention (ACCESSWIRE) +5.91%
May-24-24 08:12AM	Why Is Tharimmune (THAR) Stock Moving Today? (InvestorPlace) -6.87%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-22-24 07:00AM	Tharimmune Announces 1-for-15 Reverse Stock Split (ACCESSWIRE) -16.52%
May-09-24 01:55PM	THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 (InvestorPlace)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
Apr-30-24 08:31AM	Tharimmune To Participate in Two Upcoming Investor Conferences in May (ACCESSWIRE)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-23-24 07:31AM	Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) (ACCESSWIRE)
Apr-15-24 08:31AM	Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics (ACCESSWIRE) -6.11%
Mar-06-24 07:00AM	Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire)
Mar-05-24 08:31AM	Tharimmune to Present at the Emerging Growth Conference on March 7, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
Feb-20-24 08:01AM	Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate (ACCESSWIRE)
Feb-05-24 08:30AM	Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -6.77%
08:00AM	Loading…
Jan-29-24 08:00AM	Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update (ACCESSWIRE)
Dec-11-23 08:01AM	Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients (ACCESSWIRE) -7.11%
Nov-30-23 04:01PM	Tharimmune, Inc. Announces Closing of $11 Million Public Offering (ACCESSWIRE) -12.32% -11.25%
09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-28-23 08:43AM	Why Is Tharimmune (THAR) Stock Down 70% Today? (InvestorPlace) -72.36%
Nov-27-23 09:40PM	Tharimmune, Inc. Announces Pricing of $10 Million Public Offering (ACCESSWIRE) +22.09%
08:00AM	Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) (ACCESSWIRE)
Nov-20-23 09:27AM	Why Is Tharimmune (THAR) Stock Down 8% Today? (InvestorPlace) -17.76%
Nov-17-23 07:00AM	Tharimmune Announces 1-for-25 Reverse Stock Split (ACCESSWIRE) +16.67%
Nov-07-23 08:20AM	Why Is Tharimmune (THAR) Stock Up 113% Today? (InvestorPlace) +64.87%
Nov-06-23 05:35PM	Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis (ACCESSWIRE)
Sep-22-23 08:30AM	Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. (ACCESSWIRE)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -5.56%
Sep-11-23 11:51AM	Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis (GlobeNewswire) -8.12%
Sep-08-23 02:30PM	Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-09-23 08:47AM	Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 (GlobeNewswire) +8.08%
Jul-10-23 08:47AM	Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics (GlobeNewswire)
Jul-06-23 08:30AM	Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers (GlobeNewswire)
May-15-23 08:47AM	Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson (GlobeNewswire) +5.49%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 04:05PM	Hillstream BioPharma Announces Closing of Public Offering of Common Stock (GlobeNewswire) -7.08%
08:47AM	Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences (GlobeNewswire)
Apr-27-23 09:50PM	Hillstream BioPharma Announces Pricing of Public Offering (GlobeNewswire) +53.56% -59.49%
04:00PM	Hillstream BioPharma Announces Proposed Public Offering (GlobeNewswire)
Apr-13-23 08:47AM	Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism (GlobeNewswire)
Apr-12-23 10:30AM	Hillstream BioPharmas Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow (ACCESSWIRE) +29.32%
Apr-10-23 08:47AM	Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data (GlobeNewswire) +5.67%
Mar-28-23 08:47AM	Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023 (GlobeNewswire) -5.37%
Feb-28-23 09:45AM	Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023 (GlobeNewswire) -7.63%
Feb-15-23 07:11AM	Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire)
Feb-13-23 04:15PM	Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET (GlobeNewswire) +18.87%
07:11AM	Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer (GlobeNewswire)
Feb-10-23 07:17AM	In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer (GlobeNewswire) +34.75%
Feb-08-23 07:11AM	Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias (GlobeNewswire) +10.48%
Feb-06-23 07:00AM	Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers (GlobeNewswire)
Jan-31-23 10:41AM	Why Are Hillstream BioPharma Shares Trading Over 100% Today? (Benzinga) +78.84%
07:11AM	Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers (GlobeNewswire)
Jan-17-23 11:29AM	Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023 (GlobeNewswire)
10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Dec-12-22 05:39AM	Insiders who purchased Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year recover some losses which currently stand at US$86k (Simply Wall St.) -13.32%
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) +22.36%
Nov-22-22 06:30AM	Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 (GlobeNewswire) -9.86%
Oct-18-22 08:47AM	Hillstreams New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-06-22 08:47AM	Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 08:47AM	Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20 (GlobeNewswire)
Jul-08-22 08:17AM	Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13 (GlobeNewswire)
Jul-04-22 03:35PM	A number of insiders bought Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year, which is great news for shareholders (Simply Wall St.)
Jun-27-22 08:27AM	Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments (GlobeNewswire) +17.74%
Jun-13-22 09:06AM	Why Hillstream BioPharma Shares Are Trading Higher Today? (Benzinga) +75.30%
08:00AM	Hillstream BioPharma Announces Share Repurchase Program (GlobeNewswire)
Jun-02-22 08:47AM	Hillstream BioPharma Provides Corporate Update (GlobeNewswire) -8.25%
May-05-22 08:47AM	Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022 (GlobeNewswire) -5.56%
Mar-02-22 08:37AM	Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers (GlobeNewswire)
Feb-16-22 09:40AM	Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma (GlobeNewswire) -21.90%
Feb-14-22 09:04AM	Hillstream BioPharma Provides Business Review with Key Pipeline Updates (ACCESSWIRE) -6.50%
Feb-11-22 07:15AM	SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022 (ACCESSWIRE)
Feb-01-22 09:40AM	Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression (ACCESSWIRE)
Jan-26-22 08:30AM	Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas (ACCESSWIRE)
Jan-14-22 04:00PM	Hillstream BioPharma Announces Closing of Initial Public Offering (ACCESSWIRE)
Jan-13-22 11:05AM	Justworks IPO Postponed (Investopedia) -20.98%
Jan-11-22 07:55PM	Hillstream BioPharma Announces Pricing of Initial Public Offering (ACCESSWIRE)

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MILBY RANDY	CEO	Dec 19 '24	Buy	2.12	4,600	9,752	17,534	Dec 20 08:00 PM
Appajosyula Sireesh	Chief Operating Officer	Nov 13 '24	Buy	2.02	5,000	10,096	10,758	Nov 13 05:06 PM
MILBY RANDY	CEO	Oct 08 '24	Buy	2.09	2,500	5,221	12,934	Oct 10 04:15 PM
Appajosyula Sireesh	Chief Operating Officer	Oct 08 '24	Buy	1.93	5,000	9,650	16,364	Oct 08 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

THAR

Tharimmune Inc

Upgrade your FINVIZ experience